Target Bacteria Discovery,
Microbiome Modulation,
Product Development

Target Bacteria Discovery,
Microbiome Modulation,
Product Development

NEWS: BiomX Raises $24 Million in Series A Funding.

We develop novel therapeutics to alleviate microbiome-related diseases using our 3-tier Microbiome Modulation Platform, devised by world-leading scientists.

Our technology was developed by world-leading scientists from top-tier institutions including MIT and the Weizmann Institute of Science.

LEARN ABOUT OUR LEADERSHIP

The executives, founders, investors, and board members at BiomX each have a long history of excellence that is propelling us to continued success.

LEARN ABOUT OUR OUR BUSINESS LEADERSHIP

OUR 3-TIER MICROBIOME MODULATION PLATFORM

Our end-to-end platform enables identification of target bacteria that drive microbiome dysbiosis, precision microbiome modulation through eradication or addition of specific bacteria, and high-end drug development.

Target Bacteria Discovery

Microbiome
Modulation

Product
Development

Real time discovery of novel
target bacteria through
mining the extremely complex
human microbiome

Treat disease by adding or
eradicating bacteria or phage
cocktails that are native
or engineered

Proprietary assays, processes,
and analyses to address pre-clinical
and clinical needs, leading to
commercialization

OUR INVESTORS